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Available online 13 April 2016The human embryonic stem cell line RCe017-A (RC-13) was derived under quality assured compliance with UK
regulation, EuropeanUnionDirectives and International guidance for tissue procurement, processing and storage
according to Good Manufacturing Practice (GMP) standards. The cell line was derived from a frozen and thawed
blastocyst stage embryo voluntarily donated as unsuitable or surplus to fertility requirements following informed
consent. RCe017-A (RC-13) shows normal pluripotency marker expression and differentiation to the three germ
layers in vitro. It has a mixed 47XY, +12/48XY, +1, +12 male karyotype and microsatellite PCR identity, HLA
and blood group typing data are available.
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B.V. This is an open access article unResource details
RCe017-A (RC-13) was derived from a frozen and thawed blastocyst
stage embryo that was surplus to requirement or unsuitable for clinical
use. Human embryonic stem cell (hESC) isolation, expansion and qualiﬁ-
cation were performed in facilities whose speciﬁcation, operation and
monitoring complied with GMP standards enabling; i) a fully traceable
procurement procedure with informed ethical consent which includes
provision for commercial use, ii) detailed medical history and blood
borne virus (BBV) screening of donors, and iii) compilation of a cell line
history providing details on hESCmanufacturing process and quality con-
trol testing regime.
Human ESC culture and processing were performed in a grade A
tissue culture cabinet in a grade B clean room environment moni-
tored for particulate and microbiological contamination during cell
processing in accordance with Rules and Guidance for Pharmaceuti-
cal Manufacturers and Distributors— The Orange Guide, compiled by
the UK Medicines Healthcare Products Regulatory Authority (go to:
https://www.gov.uk/guidance/good-manufacturing-practice-and-
good-distribution-practice). Accordingly, the facility was operating
under a mature Quality Management System, compliant withder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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licensure from the UKHFEA (R0136 to centre 0202) andHTA (Licens-
ing Number 22631).
hESC derivation involved whole embryo outgrowth on mitotically
inactivated human dermal ﬁbroblast (HDF) feeder cells. HDFs were
derived and manufactured according to GMP and had been approved
for clinical use by the Food and Drug Administration, USA. During
derivation on HDFs, hESCs were grown in a xeno-free cell therapy
grade media (XF KODMEM) supplemented with xeno-free human re-
combinant bFGF. hESCs were subsequently expanded in a GMP grade
serum-free medium (StemPro hESC Serum Free Medium) on a xeno-
free matrix (CellStart). The former contained bovine serum albumin
(BSA) from a Transmissible Spongiform Encephalopathy (TSE)-free
country of origin. The cell line was cryopreserved in a GMP compliant
cryopreservation solution (CryoStor CS10).
By ﬂow cytometry, RCe017-A (RC-13) expressed the pluripotency
makers Oct-4, Tra-1-60 and SSEA-4 (80.8%, 88.3% and 79.6%, respec-
tively), whereas low expression of the differentiation marker SSEA-1Fig. 1. Quality Control Certiﬁcate of Analysi(0.7%) was observed (Figs. 1 and 2). Differentiation to the three germ
layers, endoderm, ectoderm and mesoderm, was demonstrated
using embryoid body formation in vitro, and expression of the
germ layer markers α-fetoprotein, β-tubulin and muscle actin was
observed (Fig. 3).
A microsatellite PCR proﬁle has been obtained for the cell line, and
HLA Class I and II typing is available (Table 1). Blood group genotyping
gave the blood group AA (Table 1).Veriﬁcation and authentication
The cell line was analysed for genome stability by G-banding and
showed a mixed male genotype. Trisomy 12 (47XY, +12) was pres-
ent in 26 of 30 cells analysed, but a subpopulation (4 of 30 cells) has
an additional copy of chromosome 1 (48XY, +1, +12) (Fig. 4). The
cell line is free from mycoplasma contamination as determined by
RT-qPCR.s for RCe017-A (RC-13) P19A seed lot.
Fig. 1 (continued).
Fig. 2. RCe017-A (RC-13) was subjected to ﬂow cytometry analysis for markers of pluripotency with speciﬁc antibody (top row) or isotype control (bottom row) as indicated above the
histograms. Percentage staining is indicated in the Certiﬁcate of Analysis (Fig. 1).
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Fig. 3. In vitro differentiation of RCe017-A (RC-13) to ectoderm (β-tubulin III), mesoderm (muscle Actin), and endoderm (α-fetoprotein). Speciﬁc staining shown in green, cell nuclei are
counterstained with DAPI (blue).
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Ethics
Derivation of hESC from surplus to requirement and failed to
fertilise/develop embryos was approved by The Scotland A Research
Ethics Committee and local ethics board at participating fertility clinics
and conducted under licence no. R0136 from the UK HFEA with in-
formed donor consent. The processing and storage of hESC cells for
human application were conducted under licence no. 22631 from the
UK Human Tissue Authority.
Cell culture
Frozen embryos were thawed using Vitriﬁed Embryo Safety
Thawing Pack (Kitazato/Dibimed, Valencia, Spain) according to the
manufacturer's instruction and were cultured in system SAGE Quinn's
Advanced Blastocyst medium (Rochford Medical, Coventry) after Day
3 of development. Embryos were cultured at 36.5–37.5 °C, 5.0 ± 0.5%
CO2, 5.0 ± 0.5% O2 in drops under parafﬁn oil (Rochford Medical) and
transferred to fresh medium at least every 2–3 days.
By Day 8 of development, embryos were placed in derivation condi-
tions consisting of mitotically inactivated GMP grade neonatal human
dermal ﬁbroblasts (HDFs) (Forticell Biosciences, NJ, USA) on tissue cul-
ture plastic in XF KODMEM medium (Knockout-DMEM, 15% KOSR-XF,
2 mM L-glutamine, 1% MEM nonessential amino acids, 2% XF Growth
Factor Cocktail, 0.1 mM β-mercaptoethanol (ThermoFisher Scientiﬁc,
Paisley, UK) supplemented with 80 ng/ml human bFGF (ThermoFisher
Scientiﬁc). When available, cell therapy system quality reagents wereTable 1
Microsatellite PCR, blood group and HLA tissue typing results for RCe017-A (RC-13).
Microsatellite PCR results
D3S1358 1 D3S1358 2 vWA 1 vWA 2
14 17 17 18
Amelogenin 1 Amelogenin 2 D8S1179 1 D8S1179 2
X Y 13 13
D19S433 1 D19S433 2 THO1 1 THO1 2
13 14 6 8
D5S818 1 D5S818 2 D7S820 1 D7S820 2
11 12 12* 12*
Blood group genotyping
RhD RhC Rhc RhE
pos neg pos neg
Jka Jkb K k
neg pos neg pos
Do a Do b ABO
neg pos AA
HLA tissue typing
HLA Class I Type HLA-A*02, A*31; B*13, B*40; C*03, C*0
HLA Class II Type HLA-DRB1*04, DRB1*07; DRB4*01; DQ
Comment B*40 is expressed serologically as B60
*Peak falls below threshold to conﬁdently score in 1 triplicate.used. Assisted hatchingwasperformed by removing the zonapellucidae
mechanically using Swemed cutting tools (Vitrolife, Göteborg, Sweden).
HDF cells were cultured in DMEM (Lonza, Slough, UK), 10% Pharma
grade FCS (GE Healthcare (PAA), Buckinghamshire, UK) and 2 mM L-
glutamine (ThermoFisher Scientiﬁc). HDFs were mitotically inactivated
using gamma irradiation at 50 Gy using a Gammacell Elite 1000
machine. For use as a feeder layer, irradiated HDFs were plated at
50,000 cells/cm2 in XF KODMEM medium supplemented with
80 ng/ml human bFGF (ThermoFisher Scientiﬁc). Cells were cultured
at 36.5–37.5 °C, 5.0 ± 0.5% CO2, 5.0 ± 0.5% O2 and 50% medium ex-
changed 6 days a week.
The established cell line was expanded and banked using CellStart
matrix and Stempro hESC Serum Free Medium (cell therapy system
quality reagents, ThermoFisher Scientiﬁc). This contained BSA from a
TSE-free country of origin. Passaging was performed mechanically
using an EZ passage tool (ThermoFisher Scientiﬁc). hESC lines were ex-
panded to 25–30 wells of a 6-well plate and cryopreserved in 0.5–1 ml
CryoStor CS10 (Biolife Solution, Washington, USA) using an EF600-107
controlled rate freezer (Grant Instruments, Cambridge, UK) before
being stored in a −150 °C freezer (Panasonic Biomedical, Loughbor-
ough, UK).
Mycoplasma
In process mycoplasma detection was performed using Applied
Biosystems PrepSEQ™ Mycoplasma Nucleic Acid Extraction Kit and
MicroSEQ™Mycoplasma Real-Time PCR Detection Kit (ThermoFisher
Scientiﬁc (Applied Biosystems)) according to the manufacturer's
instruction.D16S539 1 D16S539 2 D2S1338 1 D2S1338 2
9 12 24 24
D21S11 1 D21S11 2 D18S51 1 D18S51 2
27 29 12 14
FGA 1 FGA 2 CSF1PO 1 CSF1PO 2
23 26 12* 12*
D13S317 1 D13S317 2 TPOX 1 TPOX 2
13 13 8 11
Rhe Fy a Fy b Fy GATA
pos pos pos neg
M N S s
pos pos neg pos
6
B1*02, DQB1*03
, C*03 is expressed serologically as Cw10, DQB1*03 is expressed serologically as DQ8.
Fig. 4.RCe017-A (RC-13)was analysed by Giemsa staining of 30metaphase spreads and showed amixedmale karyotype of 47XY,+12 (26 of 30 cells) and 48XY,+1,+12 (4 of 30 cells).
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Endotoxin levels were determined using the Kinetic-QCL assay
(Lonza) and an incubating plate reader (BioTek ELx808) according to
the manufacturer's instructions. Brieﬂy, an unknown sample was com-
pared with a standard curve of known levels of control endotoxin. An
assay was deemed valid if the coefﬁcient of correlation, r ≥ 0.980 and
the CV (%) for the standard curve was ≤10%, and the reaction time of
the negative control was greater than the reaction time of the lowest
standard on the standard curve.
Flow cytometry
Pluripotency was determined using the Human andMouse Pluripo-
tent StemCell Analysis kit (BD,Oxford, UK). Oct 3/4 and SSEA-4were in-
cluded as pluripotencymarkers, and SSEA-1 as a differentiationmarker.
FITC conjugated Tra-1-60 (BD) was used as an additional pluripotency
marker. Fixed and permeabilised cells were analysed using a FACS
Aria ﬂow cytometer (BD) or a Guava easyCyte ﬂow cytometer
(Millipore, Watford, UK). Percentage expression of each marker was
compared to isotype control or unstained cells.
Viability
Viability was determined using the Guava ViaCount assay. Brieﬂy,
the Guava ViaCount reagent (Millipore) containing a nuclear and a via-
bility dye, was mixed with a single cell suspension, incubated for 5 min
and analysed using the Guava easyCyte ﬂow cytometer (Millipore).
Total cell count, viable cell count and percentage viable cells were
obtained.
In vitro differentiation
hESCs were pre-treated for 1 h with 10 μM ROCK inhibitor in
Stempro hESC SFM (ThermoFisher Scientiﬁc) and embryoid bodies
(EBs) generated in ultra low attachment plates (Corning) for 7 days be-
fore being transferred into EBmedium (20% FBS (GE Healthcare (PAA)),
80% KO-DMEM 1 mM L-glutamine, 3.5 μM β-mercaptoethanol, 1% non-
essential amino acids (all ThermoFisher Scientiﬁc)), on glass slide tissue
culture chambers (Nunc, ThermoFisher Scientiﬁc) coated with 0.2% gel-
atin (Sigma Aldrich, Dorset, UK) at 0.1 ml/cm2 for 14 days.Immunocytochemistry
Cells were ﬁxed in 4% paraformaldehyde (ThermoFisher Scientiﬁc
(Alfa Aesar)), permeabilised using 100% ethanol (ThermoFisher Scien-
tiﬁc) and stained with AFP (1:500; Sigma), β-tubulin III (1:1000;
Sigma) and muscle-speciﬁc actin (1:50; DAKO, Glostrup, Denmark)
and secondary antibody anti mouse IgG-AlexaFluor 488 (1:200;
Sigma). Images were acquired using a Zeiss S100 Axiovert ﬂuorescence
microscope or Nikon eC1 confocal microscope.
Genomic analysis and outsourced assays
All outsourced assayswere carried out under aQuality and Technical
Agreement. DNA was extracted using the QIAamp DNA Mini kit
(Qiagen, Manchester, UK) according to the manufacturer's recommen-
dations and provided in recommended quantities to the service
providers.
Microsatellite PCR, or Short TandemRepeat analysis, was used to de-
termine cell line identity and was carried out by Public Health England.
A proﬁle was obtained for the following core alleles: vWA, D16S539,
Amelogenin, THO1, CSF1PO, D5S818, D75820, D135317 and TPOX.
Human Leukocyte Antigen (HLA) tissue typing was carried out by
the Scottish National Blood Transfusion Service.
Blood group genotyping was carried out by the Molecular Diagnos-
tics laboratory at NHSBT.
Karyotype analysis was carried out by the Western General Cytoge-
netics Laboratory (Edinburgh, UK). Live cells at 60–70% conﬂuencywere
shipped in warm containers, ﬁxed and analysed by standard G-banding
analysis. For clinical grade lines, 30 spreads were analysed.
Viral screening for cytomegalovirus (CMV), Human T-cell
lymphotropic virus (HTLV)-1, Human immunodeﬁciency virus (HIV)-
1, Hepatitis C virus (HCV), Hepatitis B virus (HBV) and Epstein–Barr
virus (EBV) was carried out by The Doctors Laboratory (London, UK).
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